Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2759 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Bianca Aprilliano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Acute Kidney Injury. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Study Objective To compare bleeding and thromboembolic events in patients receiving therapeutic doses of apixaban or rivaroxaban versus unfractionated heparin (UFH) in patients with acute kidney injury (AKI).
Design
Single‐center, retrospective, observational study.
Setting
Ascension St. John Hospital in Detroit, Michigan. Patients Hospitalized adult patients who received therapeutic doses of factor Xa inhibitors ( n = 250) or UFH ( n = 250) for at least 24 h in the setting of AKI. Measurements and Main Results After adjusting for confounding factors, patients who received a factor Xa inhibitor experienced a lower risk of composite major and clinically relevant nonmajor bleeding (CRNMB) events compared with UFH (OR: 0.57, 95% CI: 0.34–0.94; p = 0.03). There was a significantly decreased risk of CRNMB events in the factor Xa inhibitor group (OR: 0.55, 95% CI: 0.33–0.91, p = 0.02); however, no significant differences in major bleeding or venous thromboembolism (VTE) were noted.
Conclusions
Our results suggest that it may be preferable to continue patients in AKI on factor Xa inhibitors versus transitioning to UFH due to the lower risk of bleeding events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA.
- Department of Pharmacy, Wayne State University Eugene Applebaum Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA.
ORCID-Profile: Stephanie B Edwin
Zitieren
APA
Aprilliano, B., Giuliano, C., Paxton, R. A., & Edwin, S. B. (2023). Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2759
Vancouver
Aprilliano B, Giuliano C, Paxton RA, Edwin SB. Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2759
BibTeX
@article{Aprilliano2023,
author = {Aprilliano, Bianca and Giuliano, Christopher and Paxton, Renee Alexander and Edwin, Stephanie B},
title = {Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2759}
}
EUVIMED